Fred Hutch's Radich lab devised a low-cost, paper-based method to diagnose Chronic myeloid leukemia (CML). The goal is to make this diagnostic tool available in low- and middle-income countries. The test kit can be sent by patients overseas via conventional mail for testing in the U.S. Once patients are diagnosed, they are connected with treatment through The Max Foundation, which partners with Novartis and other pharmaceutical companies to provide cancer drugs free of charge to patients in need outside the U.S. in certain low and middle-income countries.
Fred Hutch and The Max Foundation have set the goal of diagnosing – and saving the life – of one CML patient per day. The partnership is built around the unique strengths of four key organizations.